Novavax, Inc. (NASDAQ:NVAX) said it has begun enrollment in a Phase 2 clinical trial of its respiratory syncytial virus (RSV) F-protein nanoparticle vaccine candidate (RSV F Vaccine), in healthy elderly subjects. The trial expects to enroll 1,600 elderly subjects at ten sites in the United States. The trial will evaluate the incidence of all respiratory illnesses due to RSV. "Today there is a significant unmet medical need for an RSV vaccine for the approximately 57 million individuals over the age of 60 in the US. This suggests that the elderly market may be the largest value driver in our RSV franchise," president and CEO Stanley Erck said. Novavax, Inc. (NASDAQ:NVAX) shares have a 52-week spread of $2.68 - $6.95.Eagle Rock Energy Partners, L.P. (NASDAQ:EROC), an oil and gas company, said on Tuesday that it has amended its five-year senior secured credit facility originally entered into in June 2011 with several banks including Wells Fargo & Co. (WFC), Bank of America (BAC) and Royal Bank of Scotland (RBS). Commitments for the renewed facility total $320 million, with the ability to increase up to $1.2 billion. The credit matures in October 2019, extended from Eagle Rock's former agreement, as amended, which was scheduled to mature in June 2016. The amended agreement will be reviewed on a semi-annual basis, with the next redetermination in April 2015.The Regency Energy Partners units that Eagle Rock Energy Partners, L.P. (NASDAQ:EROC) received as part of its midstream business contribution are not collateralized under the credit facility agreement. The amended credit agreement is a more traditional reserve-based facility for a pure-play upstream MLP, and includes revised covenants and improved fee pricing, including a total leverage ration of no great than four times LTM EBITDA, a current ration of no less that 1 times, removal of a senior secured leverage ratio covenant, removal of an interest coverage ratio covenant and improved fee pricing by 25 basis points on all tranches except the commitment fee, which remains relatively the same.Skyworks Solutions Inc (NASDAQ:SWKS), the producer of analog semiconductors raised its guidance for fiscal Q4 earnings and revenue. SWKS has traded in a 52-week range of $23.27 to $59.25. Skyworks Solutions Inc (NASDAQ:SWKS) said it now expects Q4 adjusted earnings per diluted share of $1.08, up 69% from the prior-year period and above the $1 per share it had forecast in July. Analysts polled by Capital IQ were recently expecting $1.01. It now sees Q4 revenue at $718 million, up 51% from the year-earlier period and above its July guidance of $680 million. Analysts' latest mean estimate had been $681.9 million.The boosted outlook "demonstrates the broad-based strength of our business and our ability to capitalize on positive underlying market trends to connect everyone and everything, all the time," said David J. Aldrich, chairman and CEO. "These multi-year technology trends are setting the stage for us to outperform the broader semiconductor industry in the December quarter and for the foreseeable future." The company plans to provide its full Q4 results on Nov. 6.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
